Directional Atherectomy with Antirestenotic Therapy for Femoropopliteal Artery Disease: A Systematic Review and Meta-Analysis

• Published in: Journal of vascular and interventional radiology Vol. 30; no. 10; pp. 1586 - 1592
• Main Authors: Zhen, Yanhua, Chang, Zhihui, Wang, Chuanzhuo, Liu, Zhaoyu, Zheng, Jiahe
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2019
• Subjects: Aged; Aged, 80 and over; Angioplasty, Balloon - adverse effects; Angioplasty, Balloon - instrumentation; Atherectomy - adverse effects; Cardiovascular Agents - adverse effects; Cardiovascular Agents - therapeutic use; Coated Materials, Biocompatible; Female; Femoral Artery - diagnostic imaging; Femoral Artery - physiopathology; Humans; Male; Middle Aged; Peripheral Arterial Disease - diagnostic imaging; Peripheral Arterial Disease - physiopathology; Peripheral Arterial Disease - therapy; Popliteal Artery - diagnostic imaging; Popliteal Artery - physiopathology; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency; RR; RCT; CI; DAART; POBA; TLR; FPAD; DA; PCB
• ISSN: 1051-0443; 1535-7732
• DOI: 10.1016/j.jvir.2019.06.012

Systematic literature searches using Embase, PubMed, and Cochrane Library for directional atherectomy with antirestenotic therapy (DAART) in femoropopliteal artery disease (FPAD) from January 2003 to February 2018 were conducted to evaluate clinical safety and effectiveness. A meta-analysis was conducted using Stata software for the event rate of technical success, bailout stent placement, primary patency, and target lesion revascularization (TLR) at 12 months. Five studies with 189 patients who received DAART were included in the meta-analysis. Pooled rates of technical success and bailout stent placement were 90.4% (95% confidence interval [CI] 86.3%–94.6%) and 4.8% (95% CI 0.7%–8.9%), respectively. Primary patency and TLR at 12 months were 85.3% (95% CI 79.6%–91.1%) and 5.5% (95% CI 1.9%–9.1%), respectively. Meta-analysis of 3 comparative studies demonstrated that DAART was not superior in performance in clinical endpoints, including technical success, bailout stent placement, primary patency, and TLR at 12 months (relative risk [RR] 1.111, 95% CI 0.896–1.377, P = .337; RR 0.400, 95% CI 0.120–1.332, P = .135; RR 1.136, 95% CI 0.841–1.535, P = .405; and RR 0.722, 95% CI 0.291–1.789, P = .482). The data did not suggest that DAART was an improvement over paclitaxel-coated balloon angioplasty for FPAD. The theoretical advantages of DAART still require further confirmation.